1. Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
- Author
-
Eric Q. Wu, Tania M. Welzel, Yanjun Bao, Yaozhu J. Chen, Brett Pinsky, Douglas T. Dieterich, Gautam Sajeev, and Min Yang
- Subjects
Chronic hepatitis C virus ,Adult ,Male ,030213 general clinical medicine ,medicine.medical_specialty ,Nausea ,Decision Making ,Logistic regression ,Antiviral Agents ,Virus ,03 medical and health sciences ,0302 clinical medicine ,Germany ,Surveys and Questionnaires ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,ddc:610 ,Original Research ,business.industry ,Patient preferences ,Patient Preference ,General Medicine ,Hepatitis C, Chronic ,Middle Aged ,United States ,Rheumatology ,Europe ,Diarrhea ,Regimen ,Italy ,Tolerability ,Spain ,030220 oncology & carcinogenesis ,HCV ,Infectious diseases ,Drug Therapy, Combination ,Female ,Direct acting antiviral therapies ,France ,medicine.symptom ,DDA ,business ,Direct acting - Abstract
Introduction The new direct acting antiviral (DAA) therapies are able to effectively treat chronic hepatitis C (CHC). This study elicited the preferences of CHC patients for treatment attributes of new DAAs. Methods An online discrete choice experiment survey was designed to collect data from adult CHC patients in the USA, UK, France, Germany, Spain, and Italy. Patients were asked to choose from alternative hypothetical DAA options, defined by differing levels of nine attributes [i.e., treatment duration, tablet count and packaging, cure rate, required office visits when on treatment, modifications to statins or to proton pump inhibitors (PPIs), and risks of diarrhea, headache and nausea]. Logistic regression was used to assess preference for the treatment options. Results A total of 328 patients with CHC completed the survey (USA, n = 227; European countries, n = 101), with a mean age of 47.7 years (SD = 14.4) and an average 11.2 years since CHC diagnosis; 51% of patients were female. More than half (60%) of the patients had treatment for CHC. Patients significantly preferred a DAA regimen with higher cure rate, shorter treatment duration, lower risks of diarrhea, headache, and nausea (all p
- Published
- 2019